{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:05:00Z","timestamp":1789743900305,"version":"4.0.1"},"reference-count":25,"publisher":"Norwegian Medical Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.25.0498","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:00:17Z","timestamp":1774328417000},"source":"Crossref","is-referenced-by-count":0,"title":["High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008\u20132020"],"prefix":"10.4045","volume":"146","author":[{"given":"Jakob Nordberg","family":"N\u00f8rgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Lenita Falck","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias S.","family":"Sl\u00f8rdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Vik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Henrik Anderson","family":"Tvedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedda Berg","family":"Monsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Schjesvold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"ref=1","unstructured":"Lenhoff\u00a0S, Hjorth\u00a0M, Holmberg\u00a0E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7\u201311. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10607678&dopt=Abstract"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Perrot\u00a0A, Lauwers-Cances\u00a0V, Cazaubiel\u00a0T et al. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. Blood 2020; 136: 39. Crossref: http:\/\/dx.doi.org\/10.1182%2Fblood-2020-134538","DOI":"10.1182\/blood-2020-134538"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Richardson\u00a0PG, Jacobus\u00a0SJ, Weller\u00a0EA et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 2022; 387: 132\u201347. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35660812&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa2204925","DOI":"10.1056\/NEJMoa2204925"},{"key":"ref=4","unstructured":"Moreau\u00a0P, Attal\u00a0M, P\u00e9gouri\u00e9\u00a0B et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011; 117: 3041\u20134. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21098740&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182%2Fblood-2010-08-300863"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Harousseau\u00a0JL, Avet-Loiseau\u00a0H, Attal\u00a0M et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009; 27: 5720\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19826130&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2008.21.1060","DOI":"10.1200\/JCO.2008.21.1060"},{"key":"ref=6","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne blodsykdommer. Oslo: Helsedirektoratetet, 2013."},{"key":"ref=7","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne blodsykdommer. Oslo: Helsedirektoratetet, 2014."},{"key":"ref=8","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne blodsykdommer. Oslo: Helsedirektoratetet, 2015."},{"key":"ref=9","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne blodsykdommer. Oslo: Helsedirektoratetet, 2016."},{"key":"ref=10","unstructured":"Sonneveld\u00a0P, Dimopoulos\u00a0MA, Beksac\u00a0M et al. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J Clin Oncol 2021; 39: 3613\u201322. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34520219&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.21.01045"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"McCarthy\u00a0PL, Owzar\u00a0K, Hofmeister\u00a0CC et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770\u201381. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22571201&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1114083","DOI":"10.1056\/NEJMoa1114083"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"McCarthy\u00a0PL, Holstein\u00a0SA, Petrucci\u00a0MT et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol 2017; 35: 3279\u201389. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28742454&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2017.72.6679","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Greipp\u00a0PR, San Miguel\u00a0J, Durie\u00a0BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15809451&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2005.04.242","DOI":"10.1200\/JCO.2005.04.242"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Palumbo\u00a0A, Avet-Loiseau\u00a0H, Oliva\u00a0S et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33: 2863\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26240224&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2015.61.2267","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"ref=15","unstructured":"Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppf\u00f8lging av maligne blodsykdommer. Oslo: Helsedirektoratet, 2018."},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Uttervall\u00a0K, Borg Bruchfeld\u00a0J, Gran\u00a0C et al. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. Eur J Haematol 2019; 103: 247\u201354. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31231833&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fejh.13280","DOI":"10.1111\/ejh.13280"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Chakraborty\u00a0R, Muchtar\u00a0E, Kumar\u00a0S et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant 2017; 52: 34\u201340. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27548464&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fbmt.2016.214","DOI":"10.1038\/bmt.2016.214"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Attal\u00a0M, Lauwers-Cances\u00a0V, Marit\u00a0G et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782\u201391. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22571202&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1114138","DOI":"10.1056\/NEJMoa1114138"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Palumbo\u00a0A, Cavallo\u00a0F, Gay\u00a0F et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895\u2013905. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25184862&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1402888","DOI":"10.1056\/NEJMoa1402888"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Jackson\u00a0GH, Davies\u00a0FE, Pawlyn\u00a0C et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2019; 20: 57\u201373. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30559051&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1470-2045(18)30687-9","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"ref=21","unstructured":"Nye metoder. Lenalidomid - Indikasjon II. https:\/\/www.nyemetoder.no\/metoder\/lenalidomid-indikasjon-ii Lest 11.12.2025."},{"key":"ref=22","unstructured":"Myelomatoseregisteret i Midt-Norge. Myeloma Central Norway. 2024. \u00c5rsrapport. Trondheim: Myelomatoseregisteret i Midt-Norge, 2024."},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Tangen\u00a0J-M, Tj\u00f8nnfjord\u00a0GE, Gulbrandsen\u00a0N et al. Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis. BMC Cancer 2018; 18: 801. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30089450&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs12885-018-4722-x","DOI":"10.1186\/s12885-018-4722-x"},{"key":"ref=24","unstructured":"Munshi\u00a0PN, Vesole\u00a0D, Jurczyszyn\u00a0A et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 2020; 126: 5077\u201387. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32965680&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fcncr.33171"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Gertz\u00a0MA, Ansell\u00a0SM, Dingli\u00a0D et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008; 83: 1131\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18828972&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4065%2F83.10.1131","DOI":"10.4065\/83.10.1131"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["H\u00f8ydosebehandling med autolog stamcellest\u00f8tte ved myelomatose i Norge 2008\u201320"],"language":"no","deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:15:25Z","timestamp":1789740925000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2026\/03\/originalartikkel\/hoydosebehandling-med-autolog-stamcellestotte-ved-myelomatose-i-norge-2008-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,21]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.25.0498","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}